All Studies · Oncology · Ahmed (2014)

Ahmed (2014)

Low · Other · Preliminary (Observational/Qualitative) · n = 34
Quality Index (Adjusted QI) 0.620
0 Low < 0.56 Moderate 0.56–0.77 High ≥ 0.78 1
Study Details
ConditionAcute pain during anti-GD2 monoclonal antibody therapy for neuroblastoma
Clinical domainOncology
PopulationPediatric cancer patients
Sample sizen = 34
Country / SettingUSA - pediatric oncology clinic
Protocol clusterGeneral/Varied KY
DurationSingle-session meditation during 3F8 infusions; 112 sessions over 10-month period (voluntary, day-to-day)
Control typeUsual Care
ComparatorStandard care
Outcomes & Effect Sizes
Primary outcomePain (analgesic dose reduction during immunotherapy)
Scales usedAnxiety; QOL scales; feasibility measures
Key resultFeasibility confirmed; anxiety decreased; QOL improved
Effect sized = 0.35 (anxiety); small effect; feasibility primary outcome
ES value0.35 (d)
Retention85% (17/20 completed)
SafetyNo adverse events; well-tolerated during treatment
View PDF
Methodological Summary

Feasibility pilot; oncology setting; small sample; feasibility primary

KY Protocol Components

Mantram Meditation for Pediatric Anti-GD2 MoAb 3F8 Pain PROTOCOL: Single-session meditation intervention during immunotherapy treatment. TECHNIQUE: Mantram (chanting/mantra) meditation — rhythmic, melodic sounds to slow breathing and induce relaxation response. SETTING: Outpatient pediatric oncology clinic during anti-GD2 monoclonal antibody (3F8) infusions. DELIVERY: Administered during treatment sessions to manage acute infusion-related pain. FEASIBILITY: 71% of patients completed a session at first (n=19) or second attempt (n=5). OUTCOME: Patients received fewer analgesic doses when participating in meditation (mean = 0.4 dose, p < 0.01). NOTE: This is specifically mantram/mantra meditation applied during acute medical procedures, not a multi-session KY class program. Retrospective analysis of children with neuroblastoma.

Quality Item Scores — 1 fail · 2 partial · 3 pass · ★ critical
★A1
2
A2
3
★B2
2
★B5
1
B6
2
★B7
1
★B8
3
B9
2
JP1
3
Critical fails2
Raw QI0.704
SAF0.88
Adjusted QI0.620
Final ratingLow